Table 2.
Summary of salivary metabolites differentially expressed in poorly controlled vs. well-controlled type I diabetes.
| Metabolite compound ID | VIP | P value∗ | Fold change∗∗ |
|---|---|---|---|
| (1967 peaks) | 0.1–2.4 | 0.001–1 | −475, −733.6 |
| (4Z)-4-(3,3-Dimethyltriazanylidene)-4H-imidazole-5-carboxamide | 1.4 | 0.016 | 1.5 |
| 17β-Estradiol 3-benzoate | 1.5 | 0.101 | 1.4 |
| 2-Isopropyl-4a-methyl-8-methylenedecahydro-1-naphthalenol | 1.3 | 0.118 | −3.8 |
| 2-Methyl-3-ketovaleric acid | 1.2 | 0.302 | −1.3 |
| 2-Oxo-4-methylthiobutanoic acid | 1.4 | 0.044 | 1.7 |
| 5,6-Dihydrouridine | 1.1 | 0.212 | 1.3 |
| APGPR enterostatin | 1.3 | 0.173 | −2 |
| Androsterone glucuronide | 1.1 | 0.234 | 2 |
| Coumarin | 1.1 | 0.081 | 2.7 |
| Cytidine monophosphate N-acetylneuraminic acid | 1.4 | 0.359 | −1.6 |
| D-Arginyl-L-arginyl-D-isoleucine | 1.1 | 0.308 | −1.3 |
| DG (14:1/25:0/0:0) | 1.4 | 0.177 | −1.9 |
| DL-Glutamine | 2 | 0.051 | 1.2 |
| DL-Asparagine | 1.6 | 0.062 | −1.5 |
| Deoxypyridinoline | 1.4 | 0.136 | 1.5 |
| Dopamine | 1 | 0.91 | 1 |
| Edoxudine | 1.7 | 0.026 | −1.3 |
| GPA (4:0/18:3) | 1.6 | 0.068 | 1.5 |
| GPSer (9:0/12:0) | 1.8 | 0.049 | 2.1 |
| Glycyl-phenylalanine | 1.2 | 0.434 | 1.2 |
| Glycylproline | 1.8 | 0.086 | 1.3 |
| L-Acetylcarnitine | 1.1 | 0.567 | −1.2 |
| L-Proline | 1.5 | 0.105 | 1.4 |
| N-Acetyl-L-phenylalanine | 1.2 | 0.761 | 1.1 |
| N-Glycolylneuraminic acid | 1.7 | 0.041 | 2.7 |
| N6-Acetyl-L-lysine | 1 | 0.766 | −1.1 |
| Ne, Ne dimethyllysine | 1 | 0.927 | 1 |
| PE (24:0/18:2 (9Z,12Z)) | 1.9 | 0.044 | −2.3 |
| Paramethasone | 1.1 | 0.578 | 1.2 |
| Salicylic acid | 1 | 0.268 | 1.7 |
| Stearic acid | 1.7 | 0.037 | −1.7 |
| Tyrosyl-proline | 1.8 | 0.015 | 1.9 |
∗ t-test with Satterthwaite correction. ∗∗A positive fold change indicates mean of poorly controlled > mean of well controlled. VIP, variable influence on projection.